Elekta to launch MRI-LINAC machines in Telangana
These machines precisely finds the location of cancer cells while not affecting other areas in the body
image for illustrative purpose
Hyderabad: Elekta, a radiation therapy machine manufacturer, has announced plans to launch Magnetic Resonance Imaging Guided Linear Accelerator (MRI-LINAC) machines with the name ‘Elekta Unity’ in Telangana. The MRI-LINAC machine precisely finds the location of cancer cells and doesn’t affect other areas in the body.
The company has installed over 300 Linear Accelerator machines out of its 500 above radiotherapy machines in cancer care facilities in India. The company recently launched ACCESS 2025 strategy to improve treatment availability, enhance awareness and education, and strengthen partnerships with healthcare providers and organisations.
With 22 lakh cancer cases registering in India, there is a need of large number of equipment to treat the diseases and half of them to undergo radiation therapy. In India less than 0.4 of Linear Accelerator (LINAC) machines, which used mostly for radiation therapy, out of ten lakh people. So, Elekta came up with the manufacture and supply of Linac machines in India.
The company designs and manufactures the low-cost radiation therapy equipment for India especially according to the needs of Tier-2, Tier-3 cities as there are more cancer cases registering.
Manikandan Bala, Managing Director, Elekta India, and Senior Vice President, Intercontinental, Elekta, said: “we acknowledge the concerns surrounding India’s cancer care scenario, including equitable access to care, affordability, the migration of patients to urban cities for treatment, and the shortage of skilled manpower. We are also committed to addressing these challenges by focusing on key arears such as improving awareness, affordability, and accessibility in cancer care.”
By working closely with stakeholders and implementing innovative solutions, we aim to make high-quality cancer treatment accessible to all individuals in need, Bala added.